Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Badal

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
American Journal of Clinical Pathology|October 1, 1982
Direct comparison of two mechanized systems for identification of gram-negative bacilli. Autobac ID system versus the auto microbic system (with EBC plus)A L Barry, T L Gavan, R E Badal, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1982
Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibitionA L Barry, R N Jones, H W Wilson, et al.
Journal of Clinical Microbiology|May 1, 1982
Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazoneC Thornsberry, A L Barry, R N Jones, et al.
Journal of Global Antimicrobial Resistance|November 23, 2016
Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013S H Lob, D J Biedenbach, R E Badal, et al.
The Journal of Antibiotics|January 1, 1979
Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicinR N Jones, R R Packer, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1981
Antibacterial activity of fortimicin A compared with those of five other aminoglycosides, and factors affecting susceptibility testsC Thornsberry, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1980
Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycinC Thornsberry, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1979
Piperacillin susceptibility tests by the single-disk agar diffusion techniqueA L Barry, C Thornsberry, R E Badal, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1980
Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibioticsR N Jones, C Thornsberry, A L Barry, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2011
Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009)S P Hawser, S K Bouchillon, C Lascols, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
American Journal of Clinical Pathology|October 1, 1982
Direct comparison of two mechanized systems for identification of gram-negative bacilli. Autobac ID system versus the auto microbic system (with EBC plus)A L Barry, T L Gavan, R E Badal, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1982
Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibitionA L Barry, R N Jones, H W Wilson, et al.
Journal of Clinical Microbiology|May 1, 1982
Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazoneC Thornsberry, A L Barry, R N Jones, et al.
Journal of Global Antimicrobial Resistance|November 23, 2016
Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013S H Lob, D J Biedenbach, R E Badal, et al.
The Journal of Antibiotics|January 1, 1979
Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicinR N Jones, R R Packer, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1981
Antibacterial activity of fortimicin A compared with those of five other aminoglycosides, and factors affecting susceptibility testsC Thornsberry, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1980
Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycinC Thornsberry, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1979
Piperacillin susceptibility tests by the single-disk agar diffusion techniqueA L Barry, C Thornsberry, R E Badal, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1980
Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibioticsR N Jones, C Thornsberry, A L Barry, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2011
Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009)S P Hawser, S K Bouchillon, C Lascols, et al.
Pageof 2